GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioMarin Pharmaceutical Inc (NAS:BMRN) » Definitions » EV-to-FCF

BMRN (BioMarin Pharmaceutical) EV-to-FCF : 16.70 (As of Jul. 04, 2025)


View and export this data going back to 1999. Start your Free Trial

What is BioMarin Pharmaceutical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioMarin Pharmaceutical's Enterprise Value is $10,357 Mil. BioMarin Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $620 Mil. Therefore, BioMarin Pharmaceutical's EV-to-FCF for today is 16.70.

The historical rank and industry rank for BioMarin Pharmaceutical's EV-to-FCF or its related term are showing as below:

BMRN' s EV-to-FCF Range Over the Past 10 Years
Min: -7283.59   Med: -33.51   Max: 886.53
Current: 16.7

During the past 13 years, the highest EV-to-FCF of BioMarin Pharmaceutical was 886.53. The lowest was -7283.59. And the median was -33.51.

BMRN's EV-to-FCF is ranked worse than
62.12% of 396 companies
in the Biotechnology industry
Industry Median: 6.93 vs BMRN: 16.70

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-07-04), BioMarin Pharmaceutical's stock price is $57.50. BioMarin Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $2.690. Therefore, BioMarin Pharmaceutical's PE Ratio (TTM) for today is 21.38.


BioMarin Pharmaceutical EV-to-FCF Historical Data

The historical data trend for BioMarin Pharmaceutical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMarin Pharmaceutical EV-to-FCF Chart

BioMarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -305.99 88.09 430.03 352.51 25.25

BioMarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.86 73.06 43.43 25.25 20.78

Competitive Comparison of BioMarin Pharmaceutical's EV-to-FCF

For the Biotechnology subindustry, BioMarin Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's EV-to-FCF falls into.


;
;

BioMarin Pharmaceutical EV-to-FCF Calculation

BioMarin Pharmaceutical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10356.725/620.182
=16.70

BioMarin Pharmaceutical's current Enterprise Value is $10,357 Mil.
BioMarin Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $620 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioMarin Pharmaceutical  (NAS:BMRN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BioMarin Pharmaceutical's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=57.50/2.690
=21.38

BioMarin Pharmaceutical's share price for today is $57.50.
BioMarin Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.690.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioMarin Pharmaceutical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioMarin Pharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Executives
Erin Burkhart officer: GVP, Chief Accounting Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Charles Greg Guyer officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
George Eric Davis officer: VP, General Counsel C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jean Jacques Bienaime director, officer: Chief Executive Officer 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Robert Ajer officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs officer: Chief Medical Officer C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
V Bryan Lawlis director
Richard A Meier director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon director 770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey director C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612